KELI-401

N/A

Report date: 2024/11/11 17:56:43

Base Information

Drug NameKELI-401

Drug Alias NameKELI-401

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryLithuania

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKeli Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesKeli Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A